The U.S. Senate Committee on Health, Education, Labor, and Pensions has ordered that a proposed bill (S.959), which would amend the Food, Drug, and Cosmetic Act to give the U.S. Food and Drug Administration (FDA) authority over compounded drugs, be reported favorably, and it has been placed on the Senate’s legislative calendar. Introduced by Sen. Tom Harkin (D-Iowa), the bill has drawn the concern of the natural health community, which has instituted a citizen campaign to oppose it. Advocacy organization Citizens for Health claims that the measure would give FDA the authority to “reduce or eliminate bioidentical hormone replacement therapy [and] stem cell research,” and give the agency “broad and unprecedented power to regulate compounding pharmacy [sic].” See Citizens for Health Action Alert, June 25, 2013.